Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 12:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 399 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: regional chemotherapy Clear all
Completed Phase 2 Interventional Results available

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

NCT00182793
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, cyclophosphamide, melphalan, thiotepa, adjuvant therapy, autologous-autologous tandem hematopoietic stem cell transplantation, bone marrow ablation with stem cell support, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 9, 2026, 12:18 PM EDT
Terminated Not applicable Interventional Results available

Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma

NCT01974284
View directory record Official record
Conditions
Papillary Thyroid Cancer
Interventions
percutaneous ethanol ablation
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 9, 2026, 12:18 PM EDT
Terminated Phase 2 Interventional Results available

Treatment With Nab-paclitaxel in Cutaneous SCC

NCT02076243
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
nab-paclitaxel
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Sep 9, 2026, 12:18 PM EDT
Completed Not applicable Interventional

Tobacco Cessation Via Doctors of Chiropractic

NCT00386945
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Brief counseling (Ask, Advise, Arrange)
Behavioral
Lead sponsor
Oregon Research Institute
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 25, 2011 · Synced Sep 9, 2026, 12:18 PM EDT
Recruiting Not applicable Interventional

Multi-modal Imaging of Myofascial Pain - Phase 2

NCT07322445
View directory record Official record
Conditions
Myofascial Pain
Interventions
50/50 Mixture of Lidocaine 1% injection + Bupivacaine 0.25% Injectable Solution, Dry Needling
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 9, 2026, 12:18 PM EDT
Completed Early Phase 1 Interventional

Microdevice for Evaluating Drug Response in Site in Lung Lesions

NCT03972228
View directory record Official record
Conditions
Lung Tumor, Lung Cancer
Interventions
Microdevice loaded with 19 chemotherapeutic agents
Combination Product
Lead sponsor
Oliver Jonas
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Sep 9, 2026, 12:18 PM EDT
Terminated Phase 2 Interventional

Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus

NCT00208936
View directory record Official record
Conditions
Esophageal Diseases
Interventions
Taxol, Cisplatin, 5-Fluorouracil, G-CSF
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 9, 2026, 12:18 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
Tarlatamab, Lurbinectedin, Topotecan, Amrubicin
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
25
States / cities
Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 9, 2026, 12:18 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

NCT03061812
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Rovalpituzumab tesirine, Topotecan, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
31
States / cities
Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Sep 9, 2026, 12:18 PM EDT
Completed Phase 1 Interventional

Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

NCT00379509
View directory record Official record
Conditions
Breast Cancer
Interventions
lapatinib ditosylate, TdT-mediated dUTP nick end labeling assay, gene expression analysis, microarray analysis, immunohistochemistry staining method, biopsy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 9, 2026, 12:18 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

NCT00499616
View directory record Official record
Conditions
Neuroblastoma
Interventions
carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, topotecan hydrochloride, Isotretinoin, Surgery, Filgrastim
Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 12 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
166
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 137 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 9, 2026, 12:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer

NCT00012012
View directory record Official record
Conditions
Cervical Cancer, Radiation Toxicity
Interventions
Amifostine trihydrate, Cisplatin, Intracavitary brachytherapy, External beam radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
17
States / cities
Jacksonville, Florida • Jacksonville Beach, Florida • Jascksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Sep 9, 2026, 12:18 PM EDT
Terminated Phase 3 Interventional

Photodynamic Therapy (PDT) Trial for Palliation of Cholangiocarcinoma

NCT00907413
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
ERCP and Photodynamic Therapy, ERCP only
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Charlotteville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 9, 2026, 12:18 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer

NCT00028860
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
filgrastim, carboplatin, gemcitabine hydrochloride, ifosfamide, paclitaxel, adjuvant therapy
Biological · Drug · Procedure
Lead sponsor
Tulane University Health Sciences Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Sep 9, 2026, 12:18 PM EDT
Completed Phase 2 Interventional Results available

Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence

NCT00915005
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Photon Therapy, Proton Therapy, Paclitaxel, Carboplatin
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2020 · Synced Sep 9, 2026, 12:18 PM EDT
Completed Phase 3 Interventional

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

NCT00324727
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
Interventions
melphalan, regional chemotherapy, systemic chemotherapy, hepatic artery embolization
Drug · Procedure
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years to 120 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
12
States / cities
Santa Monica, California • Englewood, Colorado • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Sep 9, 2026, 12:18 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Metabolic Surgery for Atrial Fibrillation Elimination

NCT07027969
View directory record Official record
Conditions
Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Interventions
Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment
Procedure · Drug
Lead sponsor
Ali Aminian
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 9, 2026, 12:18 PM EDT
Not listed Not applicable Interventional

Comparison of the Atmo Motility Gas Capsule System to the Reference Standard

NCT05718505
View directory record Official record
Conditions
Gastroparesis, Slow Transit Constipation, IBS
Interventions
Atmo Motility Gas Capsule System, SmartPill Monitoring System
Device
Lead sponsor
Atmo Biosciences Pty Ltd
Industry
Eligibility
22 Years to 80 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Sep 9, 2026, 12:18 PM EDT
Completed Phase 2 Interventional Results available

Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma

NCT01781728
View directory record Official record
Conditions
Pancreatic Cancer, Periampullary Adenocarcinoma
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 9, 2026, 12:18 PM EDT
Recruiting Phase 2 Interventional

EUS-RFA PANCARDINAL-1 Trial

NCT04990609
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA), Neoadjuvant Chemotherapy (NAC)
Device · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 9, 2026, 12:18 PM EDT
Terminated Phase 3 Interventional Results available

Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

NCT04163900
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
NUC-1031, Gemcitabine, Cisplatin
Drug
Lead sponsor
NuCana plc
Other
Eligibility
18 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
29
States / cities
Tucson, Arizona • Whittier, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 9, 2026, 12:18 PM EDT
Completed Phase 1 Interventional

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

NCT01304784
View directory record Official record
Conditions
HER-2 Gene Amplification
Interventions
Cisplatin, Capecitabine, Trastuzumab and MM-111, Lapatinib +/- Trastuzumab and MM-111, Paclitaxel, Trastuzumab and MM-111, Lapatinib, trastuzumab, paclitaxel, and MM-111, Docetaxel, trastuzumab and MM-111
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Denver, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Sep 9, 2026, 12:18 PM EDT
Active, not recruiting Phase 3 Interventional

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil]
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 9, 2026, 12:18 PM EDT
Completed Phase 2 Interventional

Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses

NCT05923060
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Topical Aminolevulinate, Photodynamic therapy (PDT), Red light illumination
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 9, 2026, 12:18 PM EDT